Incyte logo

INCY - Incyte Share Price

$82.68 -0.5  -0.6%

Last Trade - 9:00pm

Large Cap
Market Cap £13.27bn
Enterprise Value £11.99bn
Revenue £1.93bn
Position in Universe 635th / 6851
Unlock INCY Revenue
Relative Strength (%)
1m -0.15%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -24.6%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
753.8 1,106 1,536 1,882 2,159 2,667 2,899 3,482 +28.8%
+1,689 +242.9 +39.9
Balance Sheet
FINANCIAL BRIEF: : For the fiscal year ended 31 December 2020, IncyteCorporation revenues increased 24% to $2.67B. Net losstotaled $295.7M vs. income of $446.9M. Revenues reflectProduct increase of 17% to $2.07B, Milestone And ContractRevenue increase from $77.5M to $205M, Royalty increase of28% to $393M. Net loss reflects Other Research anddevelopment increase from $787.9M to $1.7B (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History


INCY Revenue Unlock INCY Revenue

Net Income

INCY Net Income Unlock INCY Revenue

Normalised EPS

INCY Normalised EPS Unlock INCY Revenue

PE Ratio Range

INCY PE Ratio Range Unlock INCY Revenue

Dividend Yield Range

INCY Dividend Yield Range Unlock INCY Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
INCY EPS Forecasts Unlock INCY Revenue
Profile Summary

Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib). JAKAFI (ruxolitinib) is indicated for the treatment of patients with intermediate or high risk myelofibrosis (MF) and for the treatment of patients with polycythemia vera (PV) having had an inadequate response to or are intolerant of hydroxyurea. As of December 31, 2016, the Food and Drug Administration had granted JAKAFI orphan drug status for MF, PV and essential thrombocythemia. The primary target for ICLUSIG is B Cell Receptor-ABL, an abnormal tyrosine kinase that is expressed in chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia. The Company also has a portfolio of selective janus associated kinases 1 (JAK1) inhibitors.

Last Annual December 31st, 2020
Last Interim December 31st, 2020
Incorporated April 8, 1991
Public Since April 8, 1991
No. of Shareholders: 122
No. of Employees: 1,773
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite , Nasdaq 100 , S&P Composite 1500 , S&P 500 , S&P 500 Health Care (sector),
Exchange NASDAQ Global Select Market
Shares in Issue 219,843,497
Free Float (0.0%)
Eligible for
INCY Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for INCY
Upcoming Events for INCY
Tuesday 4th May, 2021
Q1 2021 Incyte Corp Earnings Call
Tuesday 4th May, 2021
Q1 2021 Incyte Corp Earnings Release
Wednesday 26th May, 2021 Estimate
Incyte Corp Annual Shareholders Meeting
Monday 2nd August, 2021 Estimate
Q2 2021 Incyte Corp Earnings Release
Frequently Asked Questions for Incyte
What is the Incyte share price?

As of 9:00pm, shares in Incyte are trading at $82.68, giving the company a market capitalisation of £13.27bn. This share price information is delayed by 15 minutes.

How has the Incyte share price performed this year?

Shares in Incyte are currently trading at $82.68 and the price has moved by -8.52% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Incyte price has moved by -37.91% over the past year.

What are the analyst and broker recommendations for Incyte?

Of the analysts with advisory recommendations for Incyte, there are there are currently 5 "buy" , 8 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Incyte is Hold. You can view the full broker recommendation list by unlocking its StockReport.

When will Incyte next release its financial results?

Incyte is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-12-31
What is the Incyte dividend yield?

Incyte does not currently pay a dividend.

Does Incyte pay a dividend?

Incyte does not currently pay a dividend.

When does Incyte next pay dividends?

Incyte does not currently pay a dividend.

How do I buy Incyte shares?

To buy shares in Incyte you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Incyte?

Shares in Incyte are currently trading at $82.68, giving the company a market capitalisation of £13.27bn.

Where are Incyte shares listed? Where are Incyte shares listed?

Here are the trading details for Incyte:

Country of listing: United States
Exchange: NSQ
Ticker Symbol: INCY
What kind of share is Incyte?

Based on an overall assessment of its quality, value and momentum, Incyte is currently classified as a Falling Star. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Incyte share price forecast 2021?

Shares in Incyte are currently priced at $82.68. At that level they are trading at 26.13% discount to the analyst consensus target price of 0.00.

Analysts covering Incyte currently have a consensus Earnings Per Share (EPS) forecast of 3.266 for the next financial year.

How can I tell whether the Incyte share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Incyte. Over the past six months, the relative strength of its shares against the market has been -23.73%. At the current price of $82.68, shares in Incyte are trading at -6.72% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Incyte PE Ratio?

We were not able to find PE ratio data for Incyte.

Who are the key directors of Incyte?

Incyte's management team is headed by:

Julian Baker - LED
Paula Swain - EVP
Wendy Dixon - IND
Herve Hoppenot - CHM
Jean-Jacques Bienaime - IND
Paul Clancy - IND
Barry Flannelly - EVP
Wenqing Yao - EVP
Vijay Iyengar - EVP
Steven Stein - EVP
Jacqualyn Fouse - IND
Christiana Stamoulis - CFO
Dashyant Dhanak - EVP
Maria Pasquale - EVP
Who are the major shareholders of Incyte?

Here are the top five shareholders of Incyte based on the size of their shareholding:

T. Rowe Price Associates, Inc. Investment Advisor
Percentage owned: 14.83% (32.6m shares)
Baker Bros. Advisors LP Hedge Fund
Percentage owned: 14.56% (32.0m shares)
The Vanguard Group, Inc. Investment Advisor/Hedge Fund
Percentage owned: 9.17% (20.2m shares)
Wellington Management Company, LLP Investment Advisor/Hedge Fund
Percentage owned: 6.14% (13.5m shares)
BlackRock Institutional Trust Company, N.A. Investment Advisor
Percentage owned: 5.93% (13.0m shares)
Similar to INCY
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.